SCHEMBL403401

SCHEMBL403401

Cc1ccnc2c1CN(C)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.41
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
HTR2A P28223 2/20 0.37
HTR2C P28335 2/20 0.35
HTR2B P41595 1/20 0.35
HTR6 P50406 3/20 0.35
HRH1 P35367 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
C5AR1 P21730 1/20 0.35
CHRNA7 P36544 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23022293 0.86 MAOA (0.37) CYP2C19MAOAMAOBHTR2AHTR2C
SCHEMBL17624447 0.85 CCR1 (0.35) HTR2AHTR2CHTR2BC5AR1
SCHEMBL404362 0.73 CYP2C19 (0.42) CYP2C19MAOAMAOBKDM4EMEN1
SCHEMBL8271971 0.72 MAOA (0.40) CYP2C19MAOAMAOBHTR2CMEN1
SCHEMBL795850 0.72 GRM4 (0.40) HTR2AHTR2CHTR2BKDM4EALDH1A1
SCHEMBL795349 0.72 NOS3 (0.44) HTR2AHTR2CHTR2BKDM4E
SCHEMBL28169871 0.72 KMT2A (0.52) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL17984825 0.71 CYP2C19 (0.49) CYP2C19HTR6KDM4EMEN1ALDH1A1
SCHEMBL16942495 0.71 MAOA (0.46) MAOAMAOBCYP2D6
SCHEMBL19005861 0.71 NOS3 (0.42) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021032148-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-02-25 WO disclosed
US-20170267678-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2017-09-21 US disclosed
US-20170022199-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2017-01-26 US disclosed
US-9499536-B2 Tetrahydro-pyrido-pyrimidine derivatives NOVARTIS AG (CH) 2016-11-22 US disclosed
US-20140128370-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2014-05-08 US disclosed
US-8653092-B2 Tetrahydro-pyrido-pyrimidine derivatives NOVARTIS AG (CH) 2014-02-18 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-20120065183-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2012-03-15 US disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267678-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS CYP2C19 338/4885MAOA 366/4885MAOB 100/4885
US-20120065183-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS CYP2C19 338/4885MAOA 366/4885MAOB 100/4885
US-20140128370-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS CYP2C19 338/4885MAOA 366/4885MAOB 100/4885
US-20170022199-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS CYP2C19 338/4885MAOA 366/4885MAOB 100/4885
US-20110092504-A1 INHIBITORS OF PI3 KINASE PIK3CA, PIK3R1, PIK3R5 CYP2C19 1823/4885MAOA 4349/4885MAOB 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.